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Introduction  
In the UK, it is estimated that 24% of adults drink in a hazardous or harmful 
way1 (for definitions of harmful and hazardous drinking see page 6). Levels of 
self-reported hazardous and harmful drinking are lowest in the central and 
eastern regions of England (21–24% of men and 10–14% of women). They 
are highest in the North East, North West and Yorkshire and Humber (26–
28% of men, 16–18% of women)2. Hazardous and harmful drinking are 
commonly encountered among hospital attendees; approximately 20% of 
patients admitted to hospital for illnesses unrelated to alcohol are drinking at 
potentially hazardous levels3
Continued hazardous and harmful drinking can result in alcohol dependence. 
An abrupt reduction in alcohol intake in a person who has been drinking 
excessively for a prolonged period of time may result in the development of an 
alcohol withdrawal syndrome. In addition, persistent drinking at hazardous 
and harmful levels can result in damage to almost every organ or system of 
the body.  
. 
This guideline covers key areas in the investigation and management of the 
following alcohol-related conditions in adults and young people (aged 
10 years and older):  
• acute alcohol withdrawal, including seizures and delirium tremens 
• Wernicke’s encephalopathy 
• liver disease 
• acute and chronic pancreatitis. 
It does not specifically look at women who are pregnant, children younger 
than 10 years, or people with physical or mental health conditions caused by 
alcohol use, other than those listed above. 
                                                 
1 The NHS Information Centre (2009) Statistics on alcohol: England. Leeds: The Health and Social Care 
Information Centre 
2 North West Public Health Observatory (2007) Indications of public health in the English Regions 8: 
alcohol. Liverpool: Association of Public Health Observatories 
3 Royal College of Physicians (2001) Alcohol –- can the NHS afford it? Recommendations for a coherent 
alcohol strategy for hospitals. London: Royal College of Physicians 
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This is one of three pieces of NICE guidance addressing alcohol-related 
problems among people aged 10 years and older. The others are: 
• ‘Alcohol-use disorders: preventing the development of hazardous and 
harmful drinking’ NICE public health guidance 24 (2010). Available from 
www.nice.org.uk/guidance/PH24. Public health guidance on the price, 
advertising and availability of alcohol, how best to detect alcohol misuse in 
and outside primary care, and brief interventions to manage it in these 
settings. 
• ‘Alcohol-use disorders: diagnosis, assessment and management of harmful 
drinking and alcohol dependence’ (publication expected February 2011). A 
clinical guideline covering identification, assessment, pharmacological and 
psychological/psychosocial interventions, and the prevention and 
management of neuropsychiatric complications.  
The guideline will assume that prescribers will use a drug’s summary of 
product characteristics to inform decisions made with individual patients. This 
guideline recommends some drugs for indications for which they do not have 
a UK marketing authorisation at the date of publication, if there is good 
evidence to support that use. Where recommendations have been made for 
the use of drugs outside their licensed indications (‘off-label use’), these drugs 
are marked with a footnote. 
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Patient-centred care 
This guideline offers best practice advice on the care of adults and young 
people with alcohol-related physical complications.  
Treatment and care should take into account people’s needs and preferences. 
People with alcohol-related physical complications should have the 
opportunity to make informed decisions about their care and treatment, in 
partnership with their healthcare professionals. If patients do not have the 
capacity to make decisions, healthcare professionals should follow the 
Department of Health’s advice on consent (available from 
www.dh.gov.uk/consent) and the code of practice that accompanies the 
Mental Capacity Act (summary available from www.publicguardian.gov.uk). In 
Wales, healthcare professionals should follow advice on consent from the 
Welsh Assembly Government (available from www.wales.nhs.uk/consent). 
If the patient is under 16, healthcare professionals should follow the guidelines 
in ‘Seeking consent: working with children’ (available from 
www.dh.gov.uk/consent).  
Good communication between healthcare professionals and patients is 
essential. It should be supported by evidence-based written information 
tailored to the patient’s needs. Treatment and care, and the information 
patients are given about it, should be culturally appropriate. It should also be 
accessible to people with additional needs such as physical, sensory or 
learning disabilities, and to people who do not speak or read English. 
If the patient agrees, families and carers should have the opportunity to be 
involved in decisions about treatment and care. Families and carers should 
also be given the information and support they need.  
Care of young people in transition between paediatric and adult services 
should be planned and managed according to the best practice guidance 
described in ‘Transition: getting it right for young people’ (available from 
www.dh.gov.uk). 
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Terms used in this guideline 
The Guideline Development Group used the following definitions in this 
guideline. 
• Acute alcohol withdrawal The physical and psychological symptoms that 
people can experience when they suddenly reduce the amount of alcohol 
they drink if they have previously been drinking excessively for prolonged 
periods of time. 
• Alcohol dependence A cluster of behavioural, cognitive and physiological 
factors that typically include a strong desire to drink alcohol and difficulties 
in controlling its use. Someone who is alcohol-dependent may persist in 
drinking, despite harmful consequences. They will also give alcohol a 
higher priority than other activities and obligations. For further information, 
please refer to: ‘Diagnostic and statistical manual of mental disorders’ 
(DSM-IV) (American Psychiatric Association 2000) and ‘International 
statistical classification of diseases and related health problems – 10th 
revision’ (ICD-10) (World Health Organization 2007).  
• Alcohol-use disorders Alcohol-use disorders cover a wide range of 
mental health problems as recognised within the international disease 
classification systems (ICD-10, DSM-IV). These include hazardous and 
harmful drinking and alcohol dependence. 
• Coeliac axis block Pain relief by nerve block of the coeliac plexus. 
• CIWA–Ar scale The Clinical Institute Withdrawal Assessment – Alcohol, 
revised (CIWA–Ar) scale is a validated 10-item assessment tool that can be 
used to quantify the severity of the alcohol withdrawal syndrome, and to 
monitor and medicate patients throughout withdrawal. 
• Decompensated liver disease Liver disease complicated by the 
development of jaundice, ascites, bruising or abnormal bleeding and/or 
hepatic encephalopathy. 
• Harmful drinking A pattern of alcohol consumption that is causing mental 
or physical damage. 
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• Hazardous drinking A pattern of alcohol consumption that increases 
someone’s risk of harm. Some would limit this definition to the physical or 
mental health consequences (as in harmful use). Others would include the 
social consequences. The term is currently used by the World Health 
Organization to describe this pattern of alcohol consumption. It is not a 
diagnostic term. 
• Malnourishment is a state of nutrition in which a deficiency of energy, 
protein and/or other nutrients causes measurable adverse effects on 
tissue/body form, composition, function or clinical outcome. 
• Medically assisted alcohol withdrawal The deliberate withdrawal from 
alcohol by a dependent drinker under the supervision of medical staff. 
Prescribed medication may be needed to relieve the symptoms. It can be 
carried out at home, in the community or in a hospital or other inpatient 
facility. 
• Splanchnicectomy Surgical division of the splanchnic nerves and coeliac 
ganglion. 
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Key priorities for implementation 
The following recommendations have been identified as priorities for 
implementation. 
Acute alcohol withdrawal 
• For people in acute alcohol withdrawal with, or who are assessed to be at 
high risk of developing, alcohol withdrawal seizures or delirium tremens, 
offer admission to hospital for medically assisted alcohol withdrawal. 
• Healthcare professionals who care for people in acute alcohol withdrawal 
should be skilled in the assessment and monitoring of withdrawal 
symptoms and signs. 
• Follow a symptom-triggered regimen4
− in hospital or  
 for drug treatment for people in acute 
alcohol withdrawal who are: 
− in other settings where 24-hour assessment and monitoring are 
available. 
Alcohol-related liver disease 
• Refer patients with decompensated liver disease to be considered for 
assessment for liver transplantation if they:  
− still have decompensated liver disease after best management and 
3 months’ abstinence from alcohol and 
− are otherwise suitable candidates for liver transplantation5
Alcohol-related pancreatitis 
. 
• Refer people with pain from chronic alcohol-related pancreatitis to a 
specialist centre for multidisciplinary assessment.
                                                 
4 A symptom-triggered regimen involves treatment tailored to the person’s individual needs. These are 
determined by the severity of withdrawal signs and symptoms. The patient is regularly assessed and 
monitored, either using clinical experience and questioning alone or with the help of a designated 
questionnaire such as the CIWA-Ar. Drug treatment is provided if the patient needs it and treatment is 
withheld if there are no symptoms of withdrawal. 
5 For the nationally agreed guidelines for liver transplant assessment in the context of alcohol-related 
liver disease, see www.uktransplant.org.uk/ukt/about_transplants/organ_allocation/pdf/liver_advisory_ 
group_alcohol_guidelines-november_2005.pdf 
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1 Guidance 
The following guidance is based on the best available evidence. The full 
guideline (www.nice.org.uk/guidance/CG100/Guidance) gives details of the 
methods and the evidence used to develop the guidance. 
1.1 Acute alcohol withdrawal  
1.1.1 Admission to hospital 
1.1.1.1 For people in acute alcohol withdrawal with, or who are assessed 
to be at high risk of developing, alcohol withdrawal seizures or 
delirium tremens, offer admission to hospital for medically assisted 
alcohol withdrawal. 
1.1.1.2 For young people under 16 years who are in acute alcohol 
withdrawal, offer admission to hospital for physical and 
psychosocial assessment, in addition to medically assisted alcohol 
withdrawal. 
1.1.1.3 For certain vulnerable people who are in acute alcohol withdrawal 
(for example, those who are frail, have cognitive impairment or 
multiple comorbidities, lack social support, have learning difficulties 
or are 16 or 17 years), consider a lower threshold for admission to 
hospital for medically assisted alcohol withdrawal. 
1.1.1.4 For people who are alcohol dependent but not admitted to hospital, 
offer advice to avoid a sudden reduction in alcohol intake6
1.1.2 Assessment and monitoring 
 and 
information about how to contact local alcohol support services. 
1.1.2.1 Healthcare professionals who care for people in acute alcohol 
withdrawal should be skilled in the assessment and monitoring of 
withdrawal symptoms and signs. 
                                                 
6 While abstinence is the goal, a sudden reduction in alcohol intake can result in severe withdrawal in 
dependent drinkers. 
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1.1.2.2 Follow locally specified protocols to assess and monitor patients in 
acute alcohol withdrawal. Consider using a tool (such as the 
Clinical Institute Withdrawal Assessment – Alcohol, revised [CIWA–
Ar] scale7
1.1.2.3 People in acute alcohol withdrawal should be assessed 
immediately on admission to hospital by a healthcare professional 
skilled in the management of alcohol withdrawal. 
) as an adjunct to clinical judgement. 
1.1.3 Treatment for acute alcohol withdrawal 
1.1.3.1 Offer pharmacotherapy to treat the symptoms of acute alcohol 
withdrawal as follows:  




1.1.3.2 People with decompensated liver disease who are being treated for 
acute alcohol withdrawal should be offered advice from a 
healthcare professional experienced in the management of patients 
with liver disease. 
 may be offered as an alternative to a 
benzodiazepine or carbamazepine. However, it should be used 
with caution, in inpatient settings only and according to the 
summary of product characteristics. 
                                                 
7 Sullivan JT, Sykora K, Schneiderman J et al. (1989) Assessment of alcohol withdrawal: the revised 
Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). British Journal of Addiction 
84:1353-1357 
8 Benzodiazepines are used in UK clinical practice in the management of alcohol-related withdrawal 
symptoms. Diazepam and chlordiazepoxide have UK marketing authorisation for the management of 
acute alcohol withdrawal symptoms. However, at the time of writing (May 2010), alprazolam, clobazam 
and lorazepam did not have UK marketing authorisation for this indication. Informed consent should be 
obtained and documented. In addition, the summary of product characteristics (SPC) for alprazolam 
advises that benzodiazepines should be used with extreme caution in patients with a history of alcohol 
abuse. The SPC for clobazam states that it must not be used in patients with any history of alcohol 
dependence (due to increased risk of dependence). The SPC for lorazepam advises that use in 
individuals with a history of alcoholism should be avoided (due to increased risk of dependence).  
9 Carbamazepine is used in UK clinical practice in the management of alcohol-related withdrawal 
symptoms. At the time of writing (May 2010), carbamazepine did not have UK marketing authorisation 
for this indication. Informed consent should be obtained and documented. 
10 Clomethiazole has UK marketing authorisation for the treatment of alcohol withdrawal symptoms 
where close hospital supervision is also provided. However, at the time of writing (May 2010), the SPC 
advises caution in prescribing clomethiazole for individuals known to be addiction-prone and to 
outpatient alcoholics. It also advises against prescribing it to patients who continue to drink or abuse 
alcohol. Alcohol combined with clomethiazole, particularly in alcoholics with cirrhosis, can lead to fatal 
respiratory depression even with short-term use. Clomethiazole should only be used in hospital under 
close supervision or, in exceptional circumstances, on an outpatient basis by specialist units when the 
daily dosage must be monitored closely. 
NICE clinical guideline 100 – Alcohol-use disorders: physical complications 12 
1.1.3.3 Offer information about how to contact local alcohol support 
services to people who are being treated for acute alcohol 
withdrawal. 
1.1.3.4 Follow a symptom-triggered regimen11
• in hospital or  
 for drug treatment for 
people in acute alcohol withdrawal who are: 
• in other settings where 24-hour assessment and monitoring are 
available. 
1.1.4 Management of delirium tremens 
1.1.4.1 In people with delirium tremens, offer oral lorazepam12 as first-line 
treatment. If symptoms persist or oral medication is declined, give 
parenteral lorazepam12, haloperidol13 or olanzapine14
1.1.4.2 If delirium tremens develops in a person during treatment for acute 
alcohol withdrawal, review their withdrawal drug regimen. 
.  
1.1.5 Management of alcohol withdrawal seizures 
1.1.5.1 In people with alcohol withdrawal seizures, consider offering a 
quick-acting benzodiazepine (such as lorazepam15
                                                 
11 A symptom-triggered regimen involves treatment tailored to the person’s individual needs. These are 
determined by the severity of withdrawal signs and symptoms. The patient is regularly assessed and 
monitored, either using clinical experience and questioning alone or with the help of a designated 
questionnaire such as the CIWA–Ar. Drug treatment is provided if the patient needs it and treatment is 
withheld if there are no symptoms of withdrawal. 
) to reduce the 
likelihood of further seizures. 
12 Lorazepam is used in UK clinical practice in the management of delirium tremens. At the time of 
writing (May 2010), lorazepam did not have UK marketing authorisation for this indication. Informed 
consent should be obtained and documented. In addition, the SPC advises that use in individuals with a 
history of alcoholism should be avoided (due to increased risk of dependence).  
13 Haloperidol is used in UK clinical practice in the management of delirium tremens. At the time of 
writing (May 2010), haloperidol did not have UK marketing authorisation for this indication. Informed 
consent should be obtained and documented. In addition, the SPC advises caution in patients suffering 
from conditions predisposing to convulsions, such as alcohol withdrawal.  
14 Olanzapine is used in UK clinical practice in the management of delirium tremens. At the time of 
writing (May 2010), olanzapine did not have UK marketing authorisation for this indication. Informed 
consent should be obtained and documented. In addition, the SPC advises that the safety and efficacy 
of intramuscular olanzapine has not been evaluated in patients with alcohol intoxication.  
15 Lorazepam is used in UK clinical practice in the management of alcohol withdrawal seizures. At the 
time of writing (May 2010), lorazepam did not have UK marketing authorisation for this indication. 
Informed consent should be obtained and documented. In addition, the SPC advises that use in 
individuals with a history of alcoholism should be avoided (due to increased risk of dependence).  
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1.1.5.2 If alcohol withdrawal seizures develop in a person during treatment 
for acute alcohol withdrawal, review their withdrawal drug regimen. 
1.1.5.3 Do not offer phenytoin to treat alcohol withdrawal seizures. 
1.2 Wernicke’s encephalopathy 
1.2.1.1 Offer thiamine to people at high risk of developing, or with 
suspected, Wernicke’s encephalopathy. Thiamine should be given 
in doses toward the upper end of the ‘British national formulary’ 
range. It should be given orally or parenterally as described in 
recommendations 1.2.1.2 to 1.2.1.4. 
1.2.1.2 Offer prophylactic oral thiamine to harmful or dependent drinkers: 
• if they are malnourished or at risk of malnourishment or 
• if they have decompensated liver disease or 
• if they are in acute withdrawal or 
• before and during a planned medically assisted alcohol 
withdrawal. 
1.2.1.3 Offer prophylactic parenteral thiamine followed by oral thiamine to 
harmful or dependent drinkers: 
• if they are malnourished or at risk of malnourishment or 
• if they have decompensated liver disease 
and in addition 
• they attend an emergency department or  
• are admitted to hospital with an acute illness or injury.  
1.2.1.4 Offer parenteral thiamine to people with suspected Wernicke’s 
encephalopathy. Maintain a high level of suspicion for the 
possibility of Wernicke’s encephalopathy, particularly if the person 
is intoxicated. Parenteral treatment should be given for a minimum 
of 5 days, unless Wernicke’s encephalopathy is excluded. Oral 
thiamine treatment should follow parenteral therapy. 
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1.3 Alcohol-related liver disease 
1.3.1 Assessment and diagnosis of alcohol-related liver 
disease 
1.3.1.1 Exclude alternative causes of liver disease in people with a history 
of harmful or hazardous drinking who have abnormal liver blood 
test results.  
1.3.1.2 Refer people to a specialist experienced in the management of 
alcohol-related liver disease to confirm a clinical diagnosis of 
alcohol-related liver disease. 
1.3.1.3 Consider liver biopsy for the investigation of alcohol-related liver 
disease.  
1.3.1.4 When considering liver biopsy for the investigation of alcohol-
related liver disease: 
• take into account the small but definite risks of morbidity and 
mortality 
• discuss the benefits and risks with the patient and 
• ensure informed consent is obtained. 
1.3.1.5 In people with suspected acute alcohol-related hepatitis, consider a 
liver biopsy to confirm the diagnosis if the hepatitis is severe 
enough to require corticosteroid treatment. 
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1.3.2 Referral for consideration of liver transplantation 
1.3.2.1 Refer patients with decompensated liver disease to be considered 
for assessment for liver transplantation if they:  
• still have decompensated liver disease after best management 
and 3 months’ abstinence from alcohol and 
• are otherwise suitable candidates for liver transplantation16
1.3.3 Corticosteroid treatment for alcohol-related hepatitis 
. 
1.3.3.1 Offer corticosteroid17 treatment to people with severe acute 
alcohol-related hepatitis and a discriminant function18
1.3.4 Nutritional support for alcohol-related hepatitis 
 of 32 or 
more. 
1.3.4.1 Assess the nutritional requirements of people with acute alcohol-
related hepatitis. Offer nutritional support if needed19
1.4 Alcohol-related pancreatitis 
 and consider 
using nasogastric tube feeding. 
1.4.1 Diagnosis of chronic alcohol-related pancreatitis 
1.4.1.1 To inform a diagnosis of chronic alcohol-related pancreatitis use a 
combination of: 
• the person’s symptoms 
• an imaging modality to determine pancreatic structure and 
• tests of pancreatic exocrine and endocrine function. 
                                                 
16 For the nationally agreed guidelines for liver transplant assessment in the context of alcohol-related 
liver disease, see 
www.uktransplant.org.uk/ukt/about_transplants/organ_allocation/pdf/liver_advisory_group_alcohol_guid
elines-november_2005.pdf 
17 Corticosteroids are used in UK clinical practice in the management of severe alcohol-related hepatitis. 
At the time of writing (May 2010), prednisolone did not have UK marketing authorisation for this 
indication. Informed consent should be obtained and documented. 
18 Maddrey's discriminant function (DF) was described to predict prognosis in alcohol-related hepatitis 
and identify patients suitable for treatment with steroids. It is 4.6 x [prothrombin time – control time 
(seconds)] + bilirubin in mg/dl. To calculate the DF using bilirubin in micromol/l divide the bilirubin value 
by 17 (www.mdcalc.com/maddreys-discriminant-function-for-alcoholic-hepatitis). 
19 See ‘Nutrition support in adults: oral nutrition support, enteral tube feeding and parenteral nutrition’. 
Clinical guideline 32 (2006). Available from www.nice.org.uk/guidance/CG32 
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1.4.1.2 Use computed tomography as the first-line imaging modality for the 
diagnosis of chronic alcohol-related pancreatitis in people with a 
history and symptoms suggestive of chronic alcohol-related 
pancreatitis. 
1.4.2 Pancreatic surgery versus endoscopic therapy for 
chronic alcohol-related pancreatitis 
1.4.2.1 Refer people with pain from chronic alcohol-related pancreatitis to a 
specialist centre for multidisciplinary assessment. 
1.4.2.2 Offer surgery, in preference to endoscopic therapy, to people with 
pain from large-duct (obstructive) chronic alcohol-related 
pancreatitis. 
1.4.2.3 Offer coeliac axis block, splanchnicectomy or surgery to people 
with poorly controlled pain from small-duct (non-obstructive) 
chronic alcohol-related pancreatitis. 
1.4.3 Prophylactic antibiotics for acute alcohol-related 
pancreatitis 
1.4.3.1 Do not give prophylactic antibiotics to people with mild acute 
alcohol-related pancreatitis, unless otherwise indicated. 
1.4.4 Nutritional support for acute alcohol-related pancreatitis 
1.4.4.1 Offer nutritional support20
• early (on diagnosis) and 
 to people with acute alcohol-related 
pancreatitis:  
• by enteral tube feeding rather than parenterally where possible. 
                                                 
20 See ‘Nutrition support in adults: oral nutrition support, enteral tube feeding and parenteral nutrition’. 
Clinical guideline 32 (2006). Available from www.nice.org.uk/guidance/CG32 
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1.4.5 Enzyme supplementation for chronic alcohol-related 
pancreatitis 
1.4.5.1 Offer pancreatic enzyme supplements to people with chronic 
alcohol-related pancreatitis who have symptoms of steatorrhoea or 
poor nutritional status due to exocrine pancreatic insufficiency.   
1.4.5.2 Do not prescribe pancreatic enzyme supplements to people with 
chronic alcohol-related pancreatitis if pain is their only symptom. 
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2 Notes on the scope of the guidance 
NICE guidelines are developed in accordance with a scope that defines what 
the guideline will and will not cover. The scope of this guideline is available 
from www.nice.org.uk/guidance/CG100 – click on ‘How this guidance was 
produced’. 
The guideline covers the care of adults and young people (aged 10 years and 
older) who have an alcohol-use disorder and whose condition is wholly 
alcohol-attributable or where alcohol is a contributory cause. It does not cover 
the care of women who are pregnant or children younger than 10 years. 
How this guideline was developed 
NICE commissioned the National Collaborating Centre for Chronic Conditions 
(now the National Clinical Guideline Centre for Acute and Chronic Conditions) 
to develop this guideline. The Centre established a guideline development 
group (see appendix A), which reviewed the evidence and developed the 
recommendations. An independent Guideline Review Panel oversaw the 
development of the guideline (see appendix B). 
There is more information about how NICE clinical guidelines are developed 
on the NICE website (www.nice.org.uk/HowWeWork). A booklet, ‘How NICE 
clinical guidelines are developed: an overview for stakeholders, the public and 
the NHS’ (fourth edition, published 2009), is available from NICE publications 
(phone 0845 003 7783 or email publications@nice.org.uk and quote reference 
N1739). 
3 Implementation  
NICE has developed tools to help organisations implement this guidance (see 
www.nice.org.uk/guidance/CG100).  
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4 Research recommendations 
The Guideline Development Group has made the following recommendations 
for research, based on its review of evidence, to improve NICE guidance and 
patient care in the future. The Guideline Development Group’s full set of 
research recommendations is detailed in the full guideline (see section 5).  
4.1 Admission to hospital for acute alcohol withdrawal 
What is the clinical and cost effectiveness of admitting people who attend 
hospital in mild or moderate acute alcohol withdrawal for unplanned medically 
assisted alcohol withdrawal compared with no admission and a planned 
medically assisted alcohol withdrawal with regard to the outcome of long-term 
abstinence?  
Why this is important 
People presenting at a hospital who are at risk of or have alcohol withdrawal 
seizures or delirium tremens need admission for medical management. 
People with milder withdrawal are not usually admitted, but given advice and 
provided with information regarding local outpatient alcohol addiction services. 
One of the concerns with this model is that the opportunity for intervention 
may be lost and that many of these people may never contact addiction 
services. Given that abstinence is the goal, it may be that admission for these 
people maximises the likelihood of achieving this goal. The concerns with 
admission are that it is costly, the patients may not be motivated and there 
has been no opportunity for psychological input prior to the medically assisted 
withdrawal from alcohol. 
The research should aim to compare the two models of treatment with regard 
to the primary goal of abstinence. Health economic analysis should aim to 
determine the cost effectiveness of each approach. 
4.2 Dosing regimens for acute alcohol withdrawal 
What are the safety and efficacy of symptom-triggered, fixed-dosing and front-
loading regimens for the management of acute alcohol withdrawal? 
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Why this is important 
Traditionally, acute alcohol withdrawal has been managed by administering 
medication, typically benzodiazepines, according to a predetermined tapered-
dosing schedule over a specified number of days (with the option for 
additional doses for breakthrough symptoms). This is called fixed-dosing. In 
contrast, medication can be administered in response to a person’s individual 
signs and symptoms (symptom-triggered) or by giving an initial ‘loading’ dose 
(front-loading) in conjunction with a symptom-triggered or ‘as required’ 
regimen.   
The safety and efficacy of symptom-triggered or front-loading regimens in 
comparison to the ‘traditional’ fixed-dose regimen needs to be established in 
patients admitted to acute hospital settings who undergo unplanned acute 
alcohol withdrawal. Staff and patients’ experiences in conjunction with 
objective measures of acute alcohol withdrawal need to be collected. 
4.3 Drugs for the management of alcohol withdrawal 
What is the efficacy and cost effectiveness of clomethiazole compared with 
chlordiazepoxide or carbamazepine or benzodiazepines for the treatment of 
acute alcohol withdrawal with regard to the outcomes of withdrawal severity, 
risk of seizures, risk of delirium tremens, length of treatment and patient 
satisfaction? 
Why this is important 
Clomethiazole has powerful, short-acting, sedative, tranquilising and 
anticonvulsant properties which are mediated through an indirect effect on 
gamma-aminobutyric acid (GABA) receptors in the brain. It has fallen out of 
favour in many units for the management of acute alcohol withdrawal because 
of reports of dependence and concerns regarding over-sedation. These have 
been problems in the outpatient use of clomethiazole, but it has now been 
restricted to the inpatient setting, where clomethiazole may be of great value. 
There are limited studies comparing clomethiazole with other agents. As such, 
an appropriately powered study comparing clomethiazole to chlordiazepoxide 
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or carbamazepine or benzodiazepines with regard to the outcomes described 
above would help to define the role of this potentially very useful drug. 
4.4 Assessment and monitoring 
What is the clinical and cost effectiveness of interventions delivered in an 
acute hospital setting by an alcohol specialist nurse compared with those 
managed through acute hospital setting with no input from a specialist nurse? 
Why this is important 
Alcohol-related problems are an important public health problem in the UK. 
Many patients present to acute services and are managed according to local 
pharmacotherapeutic regimens. Coordination of the management of the acute 
withdrawal episode with the long-term management of the patient can be 
complex. Prevention of Wernicke’s encephalopathy, assessment for liver and 
extra-hepatic disease, therapies targetting alcohol addiction and the long-term 
management of the patient’s physical, mental and social wellbeing are all 
components of the care. It is considered that better management during the 
hospital admission may lead to better outcomes with regard to long-term 
abstinence and health. Studies investigating the impact of an alcohol 
specialist nurse on these outcomes are required. 
4.5 Wernicke’s encephalopathy 
What is the clinical and cost effectiveness of the use of parenteral versus oral 
thiamine in preventing the first onset of Wernicke’s encephalopathy in people 
undergoing medically assisted alcohol withdrawal? 
Why this is important 
Wernicke’s encephalopathy has a devastating effect on the sufferer and can 
occur when people are withdrawing from alcohol. It is thought to be caused by 
a lack of thiamine due to poor diet and/or absorption at a time of increased 
requirement for the vitamin (for cerebral functions in particular), although little 
is known about the mechanisms involved. There is some theoretical and trial 
evidence to suggest that parenteral replacement elevates blood levels more 
quickly than oral replacement, however it is not known if this is clinically 
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significant, and there is no convincing clinical evidence to suggest which route 
and dose of thiamine is most effective at preventing Wernicke’s 
encephalopathy. This is important as parenteral dosing uses additional 
resources, is unpleasant for the patient and has a very small risk of 
anaphylaxis. Having a placebo arm is probably not acceptable, given the risks 
of significant brain damage. 
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5 Other versions of this guideline 
5.1 Full guideline 
The full guideline, ‘Alcohol-use disorders: diagnosis and clinical management 
of alcohol-related physical complications’ contains details of the methods and 
evidence used to develop the guideline. It is published by the National Clinical 
Guidelines Centre for Acute and Chronic Conditions (formerly the National 
Collaborating Centre for Chronic Conditions), and is available from our 
website (www.nice.org.uk/guidance/CG100/FullGuidance). 
5.2 Quick reference guide 
A quick reference guide for healthcare professionals is available from 
www.nice.org.uk/guidance/CG100/QuickRefGuide 
For printed copies, phone NICE publications on 0845 003 7783 or email 
publications@nice.org.uk (quote reference number N2191). 
5.3 ‘Understanding NICE guidance’ 
A summary for patients and carers (‘Understanding NICE guidance’) is 
available from www.nice.org.uk/guidance/CG100/PublicInfo 
For printed copies, phone NICE publications on 0845 003 7783 or email 
publications@nice.org.uk (quote reference number N2192).  
We encourage NHS and voluntary sector organisations to use text from this 
booklet in their own information about alcohol-related physical complications. 
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6 Related NICE guidance 
Published 
Alcohol-use disorders: preventing the development of hazardous and harmful 
drinking. NICE public health guidance 24 (2010). Available from 
www.nice.org.uk/guidance/PH24 
School-based interventions on alcohol. NICE public health guidance 7 (2007). 
Available from www.nice.org.uk/guidance/PH7  
Interventions to reduce substance misuse among vulnerable young people. 
NICE public health guidance 4 (2007). Available from 
www.nice.org.uk/guidance/PH4  
Nutrition support in adults: oral nutrition support, enteral tube feeding and 
parenteral nutrition. NICE clinical guideline 32 (2006). Available from 
www.nice.org.uk/guidance/CG32 
Under development 
NICE is developing the following guidance (details available from 
www.nice.org.uk): 
• Pregnancy and complex social factors. NICE clinical guideline (publication 
expected June 2010). 
• Personal, social and health education focusing on sex and relationships 
and alcohol education. NICE public health guidance (publication date 
expected January 2011). 
• Alcohol-use disorders: diagnosis, assessment and management of harmful 
drinking and alcohol dependence. NICE clinical guideline (publication 
expected February 2011).  
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7 Updating the guideline 
NICE clinical guidelines are updated so that recommendations take into 
account important new information. New evidence is checked 3 years after 
publication, and healthcare professionals and patients are asked for their 
views; we use this information to decide whether all or part of a guideline 
needs updating. If important new evidence is published at other times, we 
may decide to do a more rapid update of some recommendations. Please see 
our website for information about updating the guideline. 
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Appendix B: The Guideline Review Panel 
The Guideline Review Panel is an independent panel that oversees the 
development of the guideline and takes responsibility for monitoring 
adherence to NICE guideline development processes. In particular, the panel 
ensures that stakeholder comments have been adequately considered and 
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 Appendix C: The algorithms 
Care pathways can be found on pages 7 and 11 of the quick reference guide, 
available from www.nice.org.uk/guidance/CG100/QuickRefGuide 
